Bioventus (BVS) Income from Non-Controlling Interests (2020 - 2026)
Bioventus (BVS) posted Income from Non-Controlling Interests of $744000.0 for Q1 2026, up 137.59% on a QoQ basis from -$2.0 million in Q4 2025, and up 208.61% year-over-year from $241078.5 in Q1 2025.
Bioventus (BVS) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Bioventus' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at $744000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 208.61% year-over-year to $744000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 41.2% YoY) and the FY2023 annual result came in at -$24.5 million, down 75.26% from the prior year.
- Income from Non-Controlling Interests was $744000.0 for Q1 2026 at Bioventus, up from -$2.0 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $10.7 million in Q4 2024 and bottomed at -$14.9 million in Q2 2023.
- A 5-year average of -$2.4 million and a median of -$1.5 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests sank 764.95% — and 2024, when it soared 786.47%.
- Bioventus' Income from Non-Controlling Interests stood at -$4.7 million in 2022, then jumped by 66.84% to -$1.6 million in 2023, then soared by 786.47% to $10.7 million in 2024, then plunged by 118.48% to -$2.0 million in 2025, then jumped by 137.59% to $744000.0 in 2026.
- Business Quant data shows BVS's Income from Non-Controlling Interests at $744000.0 in Q1 2026, -$2.0 million in Q4 2025, and $601000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.20 Bn | 175.91 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.87 Bn | 125.99 Bn | 3.81 Bn | - |
| 3 | Medtronic | 108.88 Bn | 99.66 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 68.33 Bn | 66.87 Bn | 3.61 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 47.31 Bn | 43.64 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.65 Bn | 27.53 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn | 22.00 Mn |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.55 Bn | 22.42 Bn | 2.07 Bn | -5.85 Mn |
| 10 | Bioventus | 811.59 Mn | 775.75 Mn | 90.77 Mn | 744,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 744,000.00 |
| Dec 31, 2025 | -1.98 Mn |
| Sep 27, 2025 | 601,000.00 |
| Jun 28, 2025 | 1.81 Mn |
| Mar 29, 2025 | -685,000.00 |
| Dec 31, 2024 | 10.71 Mn |
| Sep 28, 2024 | -570,000.00 |
| Jun 29, 2024 | -8.62 Mn |
| Mar 30, 2024 | -1.49 Mn |
| Dec 31, 2023 | -1.56 Mn |
| Apr 1, 2023 | -14.94 Mn |
| Dec 31, 2022 | -4.70 Mn |
| Oct 1, 2022 | -9.25 Mn |
| Apr 2, 2022 | -3.53 Mn |
| Dec 31, 2021 | 8.26 Mn |
| Oct 2, 2021 | -1.30 Mn |
| Jul 3, 2021 | -6.65 Mn |
| Apr 3, 2021 | -408,000.00 |
| Dec 31, 2020 | -525,000.00 |
| Sep 26, 2020 | -492,000.00 |